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Aims 
o Acquire a general knowledge of what is a LGMD. 
o Know the different LGMD forms and their major features. 
o Name the different genes and proteins that are involved in the LGMDs. 
o Explain the current clinical trials and gene therapy used in LGMDs with 
good perspectives. 
o Explain the different existing animal models applied in LGMD. 
Introduction 
Limb-Girdle Muscular Dystrophy (LGMD) is a progressive inherited disorder 
characterized by progressive muscular weakness that affects the voluntary 
muscles, mainly around the pelvic and shoulder regions.  
The major features and model animals in LGMDs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Autosomal recessive forms 
Disease 
 
Gene locus Affected 
gene 
CK level Cardiac 
complications 
Respiratory 
complications 
Clinical onset Mouse 
model 
LGMD2A 15q15-q21 CAPN3 Very high   Childhood Capn3–/– 
LGMD2B 2p13 DYSF Extremely high   Early adulthood SJL 
LGMD2C 13q12  SGCG Very high   Childhood Sgcg–/–  
LGMD2B 17q12-q31 SGCA Very high   Childhood Sgca–/– 
LGMD2E 4q12  SGCB Very high   Childhood Sgcb–/– 
LGMD2F 5q33-q34 SGCD Very high   Childhood Sgcd–/– 
LGMD2G 17q11-q12 TCAP Very high   Childhood - 
LGMD2H 9q31-q34 TRIM32 Very high   Young adult - 
LGMD2I 19q-13  FKRP Very high   Variable - 
LGMD2J 2q24.3 TTN Greatly elevated   Childhood - 
LGMD2K 9q34.13 POMTI Extremely high   Childhood - 
LGMD2L 11p14.3 ANO5 Greatly elevated   Adulthood - 
LGMD2M 9q31.2 FKTN Extremely high   Variable - 
LGMD2N 14q24.3 POMT2 Extremely high   Childhood - 
Autosomal dominant forms 
Disease 
 
Gene locus Affected gene CK level Cardiac 
complications 
Respiratory 
complications 
Clinical onset Mouse model 
LGMD1A 5q31 MYOT Moderately raised   Adulthood TgT57I 
LGMD1B 1q11-21 LMNA Moderately raised   Childhood - adult Lmna–/– 
LGMD1C 3p25 CAV3 Moderate to very high   Variable Cav3–/–  
LGMD1D 6q23 - Normal or mildly elevated   Early adulthood - 
LGMD1E 7q - Normal or mildly elevated   Variable - 
LGMD1F 7q31.1-q.32.2 - Normal or mildly elevated   Variable - 
Figure 1. Localization of the different proteins in the dystrophin associated glycoprotein 
complex (DGC) that are involved in LGMD forms4.      
Conclusions 
o No curative treatment. 
o Necessity of monitoring these patients to avoid some cardiac and 
respiratory complications.  
o Follow a specific exercise program to avoid contractures, 
deformations and maintain the upright position. 
o Offer psychological treatment in some cases. 
o There are promising clinical trials, gene therapy strategies and 
animal models.  
Table 1. The different autosomal recessive forms of LGMDs with the major features and their belonging animal model. 
Table 2. The different autosomal dominant forms of LGMDs with the major features and their belonging animal model. 
Gene therapy and clinical trials 
o Stem cell transplantation therapy to enhance the regenerative ability of damaged and 
degenerating muscle cells  in patients Different LGMD forms. 
o Artificial microRNA vector (miMYOT) to knockdown mutant MYOT in muscles of a 
LGMD1A mouse model (TgT57I) LGMD1A. 
o restore the α-sarcoglycan using adeno-associated virus serotype1 (AAV1) to transfer 
the alpha-sarcoglycan gene (SGCA) LGMD2D. 
o Proteasomal inhibition restores function of mis-sense mutated dysferlin LGMD2B. 
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